Söndag 6 Juli | 05:06:34 Europe / Stockholm

Kalender

Est. tid*
2026-02-12 07:30 Bokslutskommuniké 2025
2025-11-06 07:00 Kvartalsrapport 2025-Q3
2025-08-20 07:00 Kvartalsrapport 2025-Q2
2025-05-08 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-04-24 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2025-04-01 - Split ZLNA 10:1
2025-01-31 - Bokslutskommuniké 2024
2025-01-09 - Extra Bolagsstämma 2025
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-07 - Kvartalsrapport 2024-Q1
2024-04-25 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2024-04-24 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2023-04-20 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-21 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2022-04-20 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-11 - Kvartalsrapport 2021-Q1
2021-04-22 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2021-04-21 - Årsstämma
2021-02-17 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-11-11 - Extra Bolagsstämma 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-14 - Kvartalsrapport 2020-Q1
2020-04-16 - X-dag ordinarie utdelning ZLNA 0.00 NOK
2020-04-15 - Årsstämma
2020-02-14 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Zelluna är ett norskt läkemedelsbolag. Bolagets affärsinriktning är att utveckla immunoterapier mot diverse cancertillstånd. Forskning och utveckling utgår ifrån egenbaserad teknologisk plattform, där produkterna huvudsakligen vidareutvecklas som vaccin. Störst närvaro återfinns inom Europa och Nordamerika. Bolaget grundades under 2011 och har sitt huvudkontor i Oslo, Norge.
2025-07-03 12:07:55

Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to issue share options to all employees in the Company.

A total of 1,634,000 options for shares in the Company have been distributed amongst the employees and two board members. The number of options granted corresponds to 8.0% of the outstanding number of shares in the Company. The combined number of options granted under both the previous and current share option programs corresponds to 8.7% of the outstanding shares.

Each option gives the right to acquire one share in the Company. The options are granted without consideration. Pursuant to the vesting schedule for employees, 33% of the options will vest one year after the day of grant, 33% of the options will vest two years after the day of grant and the remaining 33% will vest three years after the day of grant (vesting is dependent on the option holder still being employed in the Company). For the board members, all options vest after 1 year.

The exercise price has been set at NOK 13.34 per share, which corresponds to the volume-weighted average price over the past 30 calendar days. Options that are not exercised within 7 years from the date of grant will lapse and become void.

Primary insiders in Zelluna ASA have received the following option grants, on the terms described above:

Chief Executive Officer, Namir Hassan, has been granted 550,000 share options.

Chief Financial Officer, Hans Vassgård Eid, has been granted 175,000 share options. All 23,398 options under the previous program have been terminated.

Chief Operating Officer, Anders Holm, has been granted 145,000 share options.

Head of Research, Luise Weigand, has been granted 145,000 share options.

Head of CMC, Emilie Gauthy, has been granted 80,000 share options.

Head of Clinical Operations, Øivind Foss, has been granted 70,000 share options. All 11,398 options under the previous program have been terminated.

Head of Project Management, Julia Ino, has been granted 80,000 share options.

Board Member, Bent Jakobsen, has been granted 96,000 share options.

Board Member, Eva-Lotta Allan, has been granted 6,000 share options.

For further information, please see www.zelluna.com or contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632